Patient preferences can help us to inform the weighting of different outcomes against each other.
In questions like “How much more efficacy is needed to outweight tolerability issues?” preferences by patients or other stakeholders could play a key role in quantitative benefit-risk assessments.
The 1-hour webinar takes place on October 24th at 4pm CET, 3pm UK time, and 10am ET in the US.
There will be lots of time for discussions after the presentation.
Kevin Marsh will speak in our webinar about
Do patient preference have a role in Health Technology Assessment? Current practice and future potential
Abstract: Both regulators and payers are actively exploring how they might use quantitative estimates of patient preferences to support their decisions. This is evident in initiatives such as IMI PREFER.
Does this development provide the possibility of greater alignment in the data requirements of these decision makers? While it still poses methodological challenges, the legitimacy of using patient preferences data to support regulatory decisions is easier to establish.
The societal level resource allocation involved in reimbursement decisions causes us to question the role of the patient. When issues such as the equity of resource allocation between patients are involved, what role can patients’ preference play?
This webinar will explore the role of patient preferences in reimbursement decisions, both current practice and the future potential. Starting from a quantitative benefit risk assessment (BRA) to inform a regulatory decisions, we will incrementally consider the broader set of factors relevant to reimbursement decisions – alternative comparator treatments, costs, and equity considerations – to explore whether and how a BRA might play a role in reimbursement decisions. In doing so, we will explore current practice in incorporating stakeholders (patients and others) into reimbursement decisions, and how this differs depending on the decision problem posed by payers.
Finally, we will conclude by proposing roles for patient preferences in reimbursement, and the research agenda required to determine the usefulness and feasibility of these proposal.
Kevin Marsh, PhD, is an expert in the use of preference information and decision analysis to inform health decisions, including pipeline optimisation, authorisation, reimbursement and prescription decisions, Kevin’s research interests include preference elicitation, decision modelling, and MCDA. He actively contributes to the methodological development of these techniques. Kevin currently co-chairs the ISPOR Taskforce on the use of MCDA in Health Care Decision-Making. He has applied these and other research techniques for a range of organisations, including both regulatory and industry clients. The former has included a range of UK-based, health-related organisations, such as the National Institute for Health and Care Excellence, the National Institute for Health Research, and the Department of Health.
Kevin completed his PhD at the University of Bath, specialising in economic valuation techniques. After a year at Oxford University, he joined the Matrix Knowledge Group in London, where he built their economics practice. Kevin is an active member of the Campbell and Cochrane Economic Methods Group and contributes to methodological development in the field of economic evaluation.